Last updated: April 7, 2022
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Overall Status: Active - Recruiting
Phase
N/A
Condition
Digestive System Neoplasms
Esophageal Disorders
Treatment
N/AClinical Study ID
NCT05327517
NCC3281
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with resectable cervical esophageal squamous cell carcinoma (cT1b-T4aN0-3M0);
- Cervical esophageal cancers spreads upwards to involve the hypopharynx and downwardsto involve the thoracic esophagus can also be included;
- Aged 18-75 years;
- Without any contraindication of operation;
- Hemoglobin >=90 g/L; Leukocytes >=4.0x10^9/L; Absolute neutrophil count >=1.5x10^9/L;Platelet >=100x10^9/L;Total bilirubin <=1.5 ULN; ALT <=2.5 ULN; AST <=2.5 ULN; Serumcreatinine <=1.5 ULN or creatinine clearance rate >=50 mL/min (Cocheroft-Gault);INR <=1.5 ULN; APTT <=1.5 ULN;
- Without other malignancies;
- Expected R0 resection;
- ECOG PS 0-1;
- Volunteered to participate in the study, signed the informed consent form.
Exclusion
Exclusion Criteria:
- Without other malignancies;
- With mental diseases;
- With hemorrhagic disease;
- Inoperable patients;
- Pregnant or lactating women;
- Has a history of allergy to paclitaxel or cisplatin
Study Design
Total Participants: 192
Study Start date:
April 10, 2022
Estimated Completion Date:
December 31, 2028
Connect with a study center
Cancer Hospital Chinese Academy of Medical Sciences
Beijing,
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.